| 73 | 0 | 495 |
| 下载次数 | 被引频次 | 阅读次数 |
方法学质量是衡量证据质量高低的关键内核，但证据类型繁多，不同研究设计的偏倚来源不尽相同，且国际上发布的偏倚风险评估工具种类多、研制方法与框架各有优劣，为证据评价者的选择带来困惑。因此，本文在进一步剖析方法学质量、偏倚风险及其评估工具的最新认识进展基础上，全面介绍偏倚风险评估工具的合理选择以及Latitudes网站，以加强国内研究证据方法学质量的科学评价。
Abstract：Methodological quality serves as the critical kernel for assessing the reliability of evidence. However, the diversity of evidence types means that sources of bias vary across different study designs. Moreover, the multitude of internationally published risk of bias assessment tools-each with its own strengths and weaknesses in development methods and frameworks-poses challenges for evidence evaluators in selecting the most appropriate tool. Therefore, this article provides a comprehensive introduction to the rational selection of risk of bias assessment tools and the Latitudes website, building on the latest advancements in understanding methodological quality, risk of bias, and assessment tools. The aim is to enhance the scientific evaluation of methodological quality in domestic research evidence.
[1] 李幼平,王莉,文进等. 注重证据,循证决策[J]. 中国循证医学杂志,2008(1):1-3.
[2] Shea BJ,Hamel C,Wells GA,et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews[J]. J Clin Epidemiol,2009:62(10):1013-1020.
[3] Higgins JP,Altman DG,G?tzsche PC,et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ,2011:343:d5928.
[4] Sterne JAC,Savovi? J,Page MJ,et al. Ro B 2:a revised tool for assessing risk of bias in randomised trials[J]. BMJ,2019:366:l4898.
[5] Whiting P,Savovi? J,Higgins JP,et al. ROBIS:A new tool to assess risk of bias in systematic reviews was developed[J]. J Clin Epidemiol,2016,69:225-234.
[6] 立明,吕筠. 关注循证公共卫生决策[J]. 中华流行病学杂志,2006(1):1-4.
[7] Jones MA,Higgs J. Will evidenced-based practice take the reasoning out of practice?[D]. Butterworth Heinemann,2000.
[8] Guyatt G,Rennie D,Satya-Murti S. Users' guides to the medical literature:a manual for evidence-based clinical practice[J]. JAMA,2002,287(11):1463.
[9] 玉炫,宋旭萍,王琪,等. 循证社会科学从证据到决策：来自全球证据委员会报告的启示[J]. 中国循证医学杂志,2023,23(10): 1229-1235.
[10] 李琰,李幼平,兰礼吉,等. 循证医学的证据特征研究及其伦理学分析[J]. 医学与哲学(A),2014,35(12):39-42.
[11] Haynes RB,陶铁军,孙丁. 循证医学倡导者希望卫生服务提供者和消费者关注什么样的证据[J]. 中国循证医学杂志,2004,(6):361-365.
[12] 邓可刚. 循证医学在临床实践中的应用(三)-循证医学证据的来源及分类检索[J]. 中国社区医师,2003(11):6-7.
[13] Campbell DT,Stanley JC. Experimental and quasi-experimental designs for research[M]. Ravenio books,2015.
[14] Fletcher B,Sackett DL. Canadian task force on the periodic health examination:the Periodic Health Examination[J]. CMAJ,1979,121:1193-1254.
[15] Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents[J]. Chest,1986,89(2):2S-3S.
[16] Puntillo KA. Acute pain management:operative or medical procedures and trauma[J]. Nurs Dyn,1993,2(3):14.
[17] Eccles M,Clapp Z,Grimshaw J,et al. North of England evidence based guidelines development project:methods of guideline development[J]. Bmj,1996,312(7033):760-762.
[18] Glasziou PP,Irwig L,Bain CJ,et al. How to use the evidence: assessment and application of scientific evidence[M]. NHMRC,2000.
[19] SUNY Downstate. Guide to research method:the evidence pyramid.[EB/OL].(2004-6)[2017-06-11].http://library.downstate.edu/EBM2/2100.htm.
[20] U.S.Preventive Services Task Force.Grade defini-tions[EB/OL]. USPSTF,(2012-07)[2025-01-21].https://www.uspreventiveservice staskforce.org/Page/Name/grade-definitions.
[21] Harbour R,Miller J. A new system for grading recommendations in evidence based guidelines[J]. Bmj,2001,323(7308):334-336.
[22] Linstone HA,Turoff M. The delphi method[M]. Reading,MA:AddisonWesley,1975.
[23] World Health Organization. Global programme on evidence for health policy. Guidelines for WHO guidelines.[EB/OL].(2003-03-10)[2017-06-11].http://apps.who.int/iris/bitstream/10665/68925/1/EIP_GPE_EQC_2003_1.pdf?%20ua%20=%201
[24] Tugwell P,Shea B,Boers M,et al. Evidence-based rheumatology[M]. John Wiley & Sons,2009.
[25] OCEBM Levels of Evidence Working Group.The Oxford Levels of Evidence 2[EB/OL]. Oxford Centre for Evidence-Based Medicine,(2010-01)[2025-01-21]https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.
[26] Atkins D,Eccles M,Flottorp S,et al. Systems for grading the quality of evidence and the strength of recommendations I:critical appraisal of existing approaches The GRADE Working Group[J]. BMC health services research,2004,4:1-7.
[27] The Joanna Briggs Institute Levels of Evidence and Grades of Recommendation Working Party. JBI Levels of Evidence[EB/OL]. The Joanna Briggs Institute,(2019-05)[2025-01-21]https://jbi.global/sites/default/files/2019-05/JBI-Levels-of-evidence_2014_0.pdf
[28] 廖星,谢雁鸣. 上市后中药临床安全性循证证据体评价研究[J]. 中国中西医结合杂志,2017,37(1):109-114.
[29] 杨智荣,孙凤,詹思延. 偏倚风险评估系列:(一)概述[J]. 中华流行病学杂志,2017,38(7):983-987.
[30] 许卫华. 随机对照试验偏倚风险评估方法及其运用情况调查[J]. 广州中医药大学学报,2019,36(9):1452-1458.
[31] 董碧蓉,马春华. 偏倚对系统评价质量的影响[J]. 中国临床康复,2003(3):368-369.
[32] 张彤,何文婷,费宇彤,等. 干预性队列研究的偏倚控制及其在中医领域的特殊性[J]. 中医杂志,2019,60(11):923-927.
[33] 汪洋. Cochrane偏倚风险评估工具简介[J]. 中国全科医学,2019,22(11):1322.
[34] 吴琼芳,丁泓帆,邓围,等. ROBIS:评估系统评价偏倚风险的新工具[J]. 中国循证医学杂志,2015,15(12):1454-1457.
[35] 熊俊,陈日新. 系统评价/Meta分析方法学质量的评价工具AMSTAR[J]. 中国循证医学杂志,2011,11(9):1084-1089.
[36] 王浩,唐晓宇,王和平,等. ROBINS-I:评估非随机干预性研究偏倚风险的新工具[J]. 中国循证心血管医学杂志,2018,10(7):789-793.
[37] Higgins JP,Altman DG,G?tzsche PC,et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ,2011;343:d5928.
[38] 李柄辉,訾豪,李路遥,等. 医学领域一次研究和二次研究的方法学质量(偏倚风险)评价工具[J]. 医学新知,2021,31(1):51-58.
基本信息:
中图分类号:R-03
引用信息:
[1]肖强,徐海燕,吕承强,等.加强证据方法学质量的科学评价：偏倚风险评估工具合理选择与Latitudes网站介绍[J].中国循证心血管医学杂志,2025,17(08):911-914+922.
基金信息:
江西省卫生健康中药循证评价重点实验室项目（赣卫科教字[2022]14号）; 江西省首批培养类科技创新高端人才青年项目（jxsq2019201104）
2025-08-20
2025-08-20